The stock price of Penumbra Inc (NYSE: PEN) has jumped by 0.41 compared to previous close of 255.95. Despite this, the company has seen a gain of 1.46% in its stock price over the last five trading days. prnewswire.com reported 2025-06-16 that STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra’s Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif., June 16, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial.
Is It Worth Investing in Penumbra Inc (NYSE: PEN) Right Now?
Penumbra Inc (NYSE: PEN) has a price-to-earnings ratio that is above its average at 241.05x. The stock has a 36-month beta value of 0.49. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PEN is 37.54M, and at present, short sellers hold a 3.45% of that float. On June 19, 2025, the average trading volume of PEN was 525.47K shares.
PEN’s Market Performance
PEN stock saw a decrease of 1.46% in the past week, with a monthly decline of -8.72% and a quarterly a decrease of -8.04%. The volatility ratio for the week is 1.62%, and the volatility levels for the last 30 days are 1.71% for Penumbra Inc (PEN). The simple moving average for the last 20 days is -1.35% for PEN’s stock, with a simple moving average of 2.82% for the last 200 days.
Analysts’ Opinion of PEN
Many brokerage firms have already submitted their reports for PEN stocks, with BofA Securities repeating the rating for PEN by listing it as a “Buy.” The predicted price for PEN in the upcoming period, according to BofA Securities is $320 based on the research report published on March 14, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see PEN reach a price target of $305. The rating they have provided for PEN stocks is “Buy” according to the report published on January 21st, 2025.
Oppenheimer gave a rating of “Outperform” to PEN, setting the target price at $275 in the report published on December 17th of the previous year.
PEN Trading at -6.48% from the 50-Day Moving Average
After a stumble in the market that brought PEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.09% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PEN starting from O’Rourke Bridget, who sale 50 shares at the price of $259.78 back on Jun 16 ’25. After this action, O’Rourke Bridget now owns 5,373 shares of Penumbra Inc, valued at $12,989 using the latest closing price.
BRIDGET A O’ROURKE, the Director of Penumbra Inc, proposed sale 50 shares at $259.78 during a trade that took place back on Jun 16 ’25, which means that BRIDGET A O’ROURKE is holding shares at $12,989 based on the most recent closing price.
Stock Fundamentals for PEN
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.63 for the gross margin
The net margin for Penumbra Inc stands at 0.03. The total capital return value is set at 0.08. Equity return is now at value 3.50, with 2.66 for asset returns.
Based on Penumbra Inc (PEN), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at 0.81. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 85.49.
Currently, EBITDA for the company is 49.53 million with net debt to EBITDA at -2.14. When we switch over and look at the enterprise to sales, we see a ratio of 7.9. The receivables turnover for the company is 7.38for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.30.
Conclusion
To sum up, Penumbra Inc (PEN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
